摘要
萘哌地尔是一种新型的选择性α1 受体阻断剂 ,其α1 受体阻断作用具有组织选择性和受体亚型的选择性 ,并且可阻断钙通道、兴奋 5 HT1A受体。在临床上主要用于治疗高血压病和良性前列腺增生。本文就萘哌地尔的药代动力学、药效学。
Naftopidil is a new type of selective α 1 adrenoceptor antagonist.It possesses the selectivity of tissue and subtype α 1 adrenoceptor,exhibits calcium channel blocking effect and excits 5 HT 1A receptor.In clinical setting,it is mainly used to treat essential hypertension and benign prostate hyperplasia.In this paper,the pharmacodynamics,pharmacokinetics,initial clinical trials,and safety of naftopidil were reviewed.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2001年第8期579-582,共4页
Chinese Journal of New Drugs